controlled trial course recombinant human interferon-alpha chronic delta type hepatitis multicenter Italian study long-term therapy recombinant interferon-alpha course chronic delta hepatitis Italian patients disease times week mo mo treatment end study patients followed-up additional months Normalization decrease baseline serum ALT levels treated patients fourth month therapy twelfth month twenty-fourth month control group relapses mo mean mo cessation therapy Liver biopsies baseline twelfth month treatment Histological improvement decrease portal inflammation treated untreated patients Measures antiviral activity serum hepatitis delta virus RNA intrahepatic hepatitis delta antigen similar levels treated control patients treated patients percentage patients negative HDV RNA baseline interferon-alpha dosage study antiviral effect patients chronic hepatitis hepatic inflammation ALT levels duration reinstitution interferon-alpha therapy long-term control ALT levels prevent chronic liver damage 